Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 9 Meters Biopharma

9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma to Participate in the 2022 BIO International Convention
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NMTR
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
From 9 Meters Biopharma
Via AccessWire
Exposures COVID-19
Tickers NMTR
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NMTR
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Tickers NMTR
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Tickers NMTR
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NMTR
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NMTR
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NMTR
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NMTR
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
From 9 Meters Biopharma
Via AccessWire
Topics Hacking Regulatory Compliance
Exposures COVID-19 Information Security Legal
Tickers NMTR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS